Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics has announced that the first patient has been dosed in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for the treatment of X-linked retinoschisis.
Atsena Presents Positive Interim Six-Month Results From Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients With X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics reported encouraging six-month clinical trial results showing improved vision and a favorable safety profile for its gene therapy targeting X-linked retinoschisis.
Atsena Therapeutics Receives Data Monitoring Committee Recommendation To Proceed With Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients With X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics has been cleared to advance to the pivotal phase of its LIGHTHOUSE trial for a gene therapy targeting X-linked retinoschisis, with patient screening set to begin this month.
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership (PR Newswire)
UF startup Atsena Therapeutics and Genezen announced a manufacturing partnership to support the clinical development and future production of Atsena’s gene therapies for inherited retinal diseases.
Atsena Completes Part B Dosing and Advances to Pivotal Part C of LIGHTHOUSE Trial (Atsena Therapeutics)
UF startup Atsena Therapeutics announced that dosing is complete in patients enrolled across all adult and pediatric cohorts in Part B of the Phase I/II/III Lighthouse Trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Alignment With FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics received FDA approval to expand its Phase 1/2 LIGHTHOUSE study of ATSN-201 into a pivotal Phase 1/2/3 trial to support a BLA submission for treating X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Positive Clinical Data From Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy designation for ATSN-201 for the treatment of X-linked retinoschisis.
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing To Further Advance Ocular Gene Therapy Programs
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing or preventing blindness, announced the successful close of an oversubscribed $150 million Series C financing round.